Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients

Impact of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Chronic Myeloid Leukemia

Registry	NCT07413263
Status	Not yet recruiting
Study type	Observational
Enrollment	75 (Estimated)
Sponsor	Assiut University (Other)
Conditions	Chronic Myeloid Leukemia
Interventions	Tyrosine kinase Inhibitors (Imatinib & Nilotinib) (Drug)
Dates	start 2026-05-01 (estimated), primary completion 2027-12-30 (estimated), completion 2028-12-30 (estimated), first posted 2026-02-17, last updated 2026-02-18

-Summary

to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism

to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism and how danger they drugs be

Tyrosine kinase Inhibitors (Imatinib & Nilotinib) (Drug): these drugs used in CML only

Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors [Baseline and 3, 6, 9, and 12 months]: Assessment of change in HbA1c levels in CML patients treated with TKIs.

Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors [Baseline and 3, 6, 9, and 12 months]: Assessment of changes in lipid profile including total cholesterol, triglycerides, LDL, and HDL in CML patients treated with TKIs.

Sex: All, accepts healthy volunteers

Inclusion Criteria:

* CML patients free medical history

Exclusion Criteria:

* diabetic

Hwang SM, Im SH, Rudra D. Signaling networks controlling ID and E protein activity in T cell differentiation and function. Front Immunol. 2022 Aug 2;13:964581. doi: 10.3389/fimmu.2022.964581. eCollection 2022. PMID 35983065